Literature DB >> 12700382

Natalizumab for relapsing multiple sclerosis.

Abhijit Chaudhuri, Peter O Behan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12700382     DOI： 10.1056/NEJM200304173481614

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses.

Authors:  María Mittelbrunn; Ana Molina; María M Escribese; María Yáñez-Mó; Ester Escudero; Angeles Ursa; Reyes Tejedor; Francisco Mampaso; Francisco Sánchez-Madrid
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

Review 2.  Lessons for clinical trials from natalizumab in multiple sclerosis.

Authors:  Abhijit Chaudhuri
Journal:  BMJ       Date:  2006-02-18

3.  SLP-76 is required for optimal CXCR4-stimulated T lymphocyte firm arrest to ICAM-1 under shear flow.

Authors:  Dooyoung Lee; Jiyeon Kim; Rebecca G Baker; Gary A Koretzky; Daniel A Hammer
Journal:  Eur J Immunol       Date:  2012-09-10       Impact factor: 5.532

Review 4.  Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?

Authors:  Roberto González-Amaro; María Mittelbrunn; Francisco Sánchez-Madrid
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

5.  Recurrence of disease activity after repeated Natalizumab withdrawals.

Authors:  Laura Ferrè; Lucia Moiola; Francesca Sangalli; Marta Radaelli; Valeria Barcella; Giancarlo Comi; Vittorio Martinelli
Journal:  Neurol Sci       Date:  2014-09-24       Impact factor: 3.307

6.  Oxidative Stress and Lymphocyte Alterations in Chronic Relapsing Experimental Allergic Encephalomyelitis in the Rat Hippocampus and Protective Effects of an Ethanolamine Phosphate Salt.

Authors:  Aranzazu Perianes-Cachero; María V T Lobo; Alberto M Hernández-Pinto; Rebeca Busto; Miguel Angel Lasunción-Ripa; Eduardo Arilla-Ferreiro; Lilian Puebla-Jiménez
Journal:  Mol Neurobiol       Date:  2019-09-10       Impact factor: 5.590
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.